您是第 11128800 位 欢迎访问 中乔新舟官网 ! 全国免费电话:400-038-9959 我的购物车(0) 注 册 / 登 录
扫码关注公众号
您当前的位置:首页 > 产品中心

SUM149PT人乳腺癌细胞(STR鉴定)

英文名:SUM149PT
货号:ZQ1096
价格:¥1500.00
加入购物车,提交订单信息之后,我们会第一时间与您取得联系!
推荐组合

SUM149PT人乳腺癌细胞(STR鉴定)

¥1500.00
+

SUM149PT人乳腺癌细胞专用培养基

¥350.00 ¥480.00

配套完培,省时省力,单买细胞无优惠

=

细胞套餐惊爆价

¥1850 ¥2280.00
加入购物车
  • 产品说明
  • 产品规格
  • 参考文献
  • STR鉴定

产品名称

SUM149PT人乳腺癌细胞

货号

ZQ1096

产品介绍

SUM149PT是一种人乳腺癌细胞系,源自一位40岁女性患者的炎性乳腺癌。是从浸润性导管癌患者的ER阴性,PR阴性和Her2阳性(未激活)炎性乳腺癌中发展而来的这种细胞系在乳腺癌的研究中具有重要的应用价值,尤其是在研究乳腺癌的生物学特性、药物筛选和病理机制方面。

种属

性别/年龄

/40岁

组织

乳腺组织

疾病

乳腺癌

细胞类型

肿瘤细胞

形态学

上皮

生长方式

贴壁

倍增时间

33.95 hours (JWGray panel)

培养基和添加剂

DMEM (中乔新舟  货号:ZQ-100)+10%胎牛血清(中乔新舟  货号:ZQ500-A+1%P/S(中乔新舟  货号:CSP006

推荐完全培养基货号

ZM1096

生物安全等级

BSL-1

培养条件

95%空气,5%二氧化碳;37℃

STR位点信息

Amelogenin: X

CSF1PO : 12

D2S1338:  20

D3S1358 : 17

D5S818 : 11

D6S1043 : 18

D7S820 : 11

D8S1179 : 14,16

D12S391:  15,18

D13S317:  12

D16S539:  11

D18S51 : 14,15

D19S433 : 12,14

D21S11:  28,31.2

FGA:  29

Penta D:  8,9

Penta E : 11

TH01:  9.3

TPOX : 9

vWA : 16,18

抗原表达/受体表达

*** 

基因表达

*** 

保藏机构

 CLS; 300609

供应限制

仅供科研使用


货号

ZQ1096

发货规格

活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一

发货形式

活细胞:常温运输;冻存管:干冰运输

储存温度

活细胞:培养箱;冻存管:液氮罐

产地

中国

供应限制

仅供科研使用

PubMed=10424408; DOI=10.1023/A:1006135331912
Ignatoski K.M.W., Ethier S.P.
Constitutive activation of pp125fak in newly isolated human breast cancer cell lines.
Breast Cancer Res. Treat. 54:173-182(1999)


PubMed=10604729; DOI=10.1038/sj.bjc.6695007
Forozan F., Veldman R., Ammerman C.A., Parsa N.Z., Kallioniemi A.H., Kallioniemi O.-P., Ethier S.P.
Molecular cytogenetic analysis of 11 new breast cancer cell lines.
Br. J. Cancer 81:1328-1334(1999)


PubMed=10700188; DOI=10.1038/73536
Gayther S.A., Batley S.J., Linger L., Bannister A.J., Thorpe K., Chin S.-F., Daigo Y., Russell P., Wilson A., Sowter H.M., Delhanty J.D.A., Ponder B.A.J., Kouzarides T., Caldas C.
Mutations truncating the EP300 acetylase in human cancers.
Nat. Genet. 24:300-303(2000)


PubMed=10969801
Forozan F., Mahlamaki E.H., Monni O., Chen Y.-D., Veldman R., Jiang Y., Gooden G.C., Ethier S.P., Kallioniemi A., Kallioniemi O.-P.
Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.
Cancer Res. 60:4519-4525(2000)


PubMed=12353263; DOI=10.1002/gcc.10107
Popovici C., Basset C., Bertucci F., Orsetti B., Adelaide J., Mozziconacci M.-J., Conte N., Murati A., Ginestier C., Charafe-Jauffret E., Ethier S.P., Lafage-Pochitaloff M., Theillet C., Birnbaum D., Chaffanet M.
Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene.
Genes Chromosomes Cancer 35:204-218(2002)


PubMed=12800145; DOI=10.1002/gcc.10218
Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B., Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A., Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D., Edwards P.A.W., Chaffanet M.
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
Genes Chromosomes Cancer 37:333-345(2003)


PubMed=15677628; DOI=10.1093/carcin/bgi032
Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C., Edwards P.A.W., Caldas C.
Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.
Carcinogenesis 26:923-930(2005)


PubMed=15857504; DOI=10.1186/1475-2867-5-11
Hoffmeyer M.R., Wall K.M., Dharmawardhane S.F.
In vitro analysis of the invasive phenotype of SUM 149, an inflammatory breast cancer cell line.
Cancer Cell Int. 5:11.1-11.10(2005)


PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853
Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M., van den Ouweland A.M.W., Merajver S.D., Ethier S.P., Schutte M.
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
Cancer Res. 66:41-45(2006)


PubMed=16541312; DOI=10.1007/s10549-006-9186-z
Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.
Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
Breast Cancer Res. Treat. 99:97-101(2006)


PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008
Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T., DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., McCormick F., Dickson R.B., Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Cancer Cell 10:515-527(2006)


PubMed=19582160; DOI=10.1371/journal.pone.0006146
Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J., Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D., Pollack J.R.
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
PLoS ONE 4:E6146-E6146(2009)


PubMed=19593635; DOI=10.1007/s10549-009-0460-8
Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F., Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J., Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M., Zwarthoff E.C., Teunisse A., van der Spek P.J., Klijn J.G.M., Dinjens W.N.M., Ethier S.P., Clevers H.C., Jochemsen A.G., den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.
Breast Cancer Res. Treat. 121:53-64(2010)


PubMed=22032724; DOI=10.1186/1755-8794-4-75
Ha K.C.H., Lalonde E., Li L.-L., Cavallone L., Natrajan R., Lambros M.B., Mitsopoulos C., Hakas J., Kozarewa I., Fenwick K., Lord C.J., Ashworth A., Vincent-Salomon A., Basik M., Reis-Filho J.S., Majewski J., Foulkes W.D.
Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines.
BMC Med. Genomics 4:75.1-75.13(2011)


DOI=10.4172/2161-0681.1000119
Robertson F.M., Chu K., Fernandez S.V., Mu Z.-M., Zhang X.-J., Liu H., Boley K.M., Alpaugh R.K., Ye Z.-M., Wright M.C., Luo A.Z., Oraes R., Wu H., Zook M., Barsky S.H., Krishnamurthy S., Cristofanilli M.
Genomic profiling of pre-clinical models of inflammatory breast cancer identifies a signature of epithelial plasticity and suppression of TGFbeta signaling.
J. Clin. Exp. Pathol. 2:119.1-119.11(2012)


PubMed=23151021; DOI=10.1186/1471-2164-13-619
Grigoriadis A., Mackay A., Noel E., Wu P.-J., Natrajan R., Frankum J., Reis-Filho J.S., Tutt A.
Molecular characterisation of cell line models for triple-negative breast cancers.
BMC Genomics 13:619.1-619.14(2012)


PubMed=23401782; DOI=10.1155/2013/872743
Barnabas N., Cohen D.
Phenotypic and molecular characterization of MCF10DCIS and SUM breast cancer cell lines.
Int. J. Breast Cancer 2013:872743.1-872743.16(2013)


PubMed=23601657; DOI=10.1186/bcr3415
Riaz M., van Jaarsveld M.T.M., Hollestelle A., Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J.-J., Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A., Martens J.W.M.
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Breast Cancer Res. 15:R33.1-R33.17(2013)


PubMed=23784380; DOI=10.1007/s10549-013-2600-4
Fernandez S.V., Robertson F.M., Pei J.-M., Aburto-Chumpitaz L.D., Mu Z.-M., Chu K., Alpaugh R.K., Huang Y., Cao Y., Ye Z.-M., Cai K.Q., Boley K.M., Klein-Szanto A.J.P., Devarajan K., Addya S., Cristofanilli M.
Inflammatory breast cancer (IBC): clues for targeted therapies.
Breast Cancer Res. Treat. 140:23-33(2013)


PubMed=24162158; DOI=10.1007/s10549-013-2743-3
Prat A., Karginova O., Parker J.S., Fan C., He X.-P., Bixby L.M., Harrell J.C., Roman E., Adamo B., Troester M.A., Perou C.M.
Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.
Breast Cancer Res. Treat. 142:237-255(2013)


PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110
Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M., Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S., Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S., Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J., Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.
Modeling precision treatment of breast cancer.
Genome Biol. 14:R110.1-R110.14(2013)


PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)


PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)


PubMed=26495931; DOI=10.1515/hmbci-2015-0024
Illera J.C., Caceres S., Pena L., de Andres P.J., Monsalve B., Illera M.J., Woodward W.A., Reuben J.M., Silvan G.
Steroid hormone secretion in inflammatory breast cancer cell lines.
Horm. Mol. Biol. Clin. Investig. 24:137-145(2015)


PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)


PubMed=26735014; DOI=10.1038/nature16508
Shu S.-K., Lin C.Y., He H.-S.H., Witwicki R.M., Tabassum D.P., Roberts J.M., Janiszewska M., Huh S.J., Liang Y., Ryan J., Doherty E., Mohammed H., Guo H., Stover D.G., Ekram M.B., Brown J., D'Santos C., Krop I.E., Dillon D., McKeown M.R., Ott C., Qi J., Ni M., Rao P.K., Duarte M., Wu S.-Y., Chiang C.-M., Anders L., Young R.A., Winer E., Letai A.G., Barry W.T., Carroll J.S., Long H., Brown M.A., Liu X.-L.S., Meyer C.A., Bradner J.E., Polyak K.
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
Nature 529:413-417(2016)


PubMed=28287265; DOI=10.1021/acs.jproteome.6b00470
Yen T.-Y., Bowen S., Yen R., Piryatinska A., Macher B.A., Timpe L.C.
Glycoproteins in claudin-low breast cancer cell lines have a unique expression profile.
J. Proteome Res. 16:1391-1400(2017)


PubMed=32416067; DOI=10.1016/j.molcel.2020.04.027
Shu S.-K., Wu H.-J., Ge J.Y., Zeid R., Harris I.S., Jovanovic B., Murphy K., Wang B.-B., Qiu X.-T., Endress J.E., Reyes J., Lim K., Font-Tello A., Syamala S., Xiao T.-F., Reddy Chilamakuri C.S., Papachristou E.K., D'Santos C., Anand J., Hinohara K., Li W., McDonald T.O., Luoma A., Modiste R.J., Nguyen Q.-D., Michel B., Cejas P., Kadoch C., Jaffe J.D., Wucherpfennig K.W., Qi J., Liu X.-L.S., Long H., Brown M.A., Carroll J.S., Brugge J.S., Bradner J.E., Michor F., Polyak K.
Synthetic lethal and resistance interactions with BET bromodomain inhibitors in triple-negative breast cancer.
Mol. Cell 78:1096-1113.e8(2020)


PubMed=32715085; DOI=10.1038/s41523-020-0173-z
Ethier S.P., Guest S.T., Garrett-Mayer E., Armeson K., Wilson R.C., Duchinski K., Couch D., Gray J.W., Kappler C.S.
Development and implementation of the SUM breast cancer cell line functional genomics knowledge base.
NPJ Breast Cancer 6:30.1-30.14(2020)


PubMed=35042871; DOI=10.1038/s41523-021-00379-6
Rypens C., Bertucci F., Finetti P., Robertson F.M., Fernandez S.V., Ueno N.T., Woodward W.A., Van Golen K., Vermeulen P., Dirix L., Viens P., Birnbaum D., Devi G.R., Cristofanilli M., Van Laere S.
Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC.
NPJ Breast Cancer 8:12.1-12.12(2022)

暂无相关产品!
公司简介 / Company profile
上海中乔新舟生物科技有限公司
Shanghai Zhong Qiao Xin Zhou Biotechnology Co.,Ltd.
      上海中乔新舟生物科技有限公司(官网:www.zqxzbio.com)成立于2011年,历经十多年发展,...
联系我们 / Contact
电 话:021-56760357;021-56760351
邮 箱:sales@zqxzbio.com
邮 编:200439
地 址:上海市宝山区长江南路180号
Copyright © 2014 ZQXZBIO All rights reserved. 网站地图

沪公网安备 31011002001038号

技术支持:攸攸网络 沪ICP备14008091号